Biotech Bubble Reaches Epic Proportions As Short Interest Rises

In January we noted that despite Janet Yellen’s “irrational exuberance” moment when, last summer, the Fed chair mentioned biotech as a sector where valuations looked “substantially stretched,” biotech stocks have continued their relentless ascent thanks in part to M&A deals worth 40 times sales and IPOs for pre-revenue companies.Now, with the sector still making new highs, the bubble chorus is […]